{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T13:33:40Z","timestamp":1793021620684,"version":"4.5.0"},"reference-count":39,"publisher":"American Association for Cancer Research (AACR)","issue":"10","license":[{"start":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T00:00:00Z","timestamp":1792972800000},"content-version":"vor","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P50 CA097186"],"award-info":[{"award-number":["P50 CA097186"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P01 CA298991"],"award-info":[{"award-number":["P01 CA298991"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA266452"],"award-info":[{"award-number":["R01 CA266452"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["219594\/Z\/19\/Z"],"award-info":[{"award-number":["219594\/Z\/19\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["T32 CA009138"],"award-info":[{"award-number":["T32 CA009138"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA077598"],"award-info":[{"award-number":["P30 CA077598"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100023520","name":"Department of Defense Education Activity","doi-asserted-by":"publisher","award":["W81XWH-22-2-0025"],"award-info":[{"award-number":["W81XWH-22-2-0025"]}],"id":[{"id":"10.13039\/100023520","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100023520","name":"Department of Defense Education Activity","doi-asserted-by":"publisher","award":["PC240157"],"award-info":[{"award-number":["PC240157"]}],"id":[{"id":"10.13039\/100023520","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Variant histologic features can emerge in therapy-resistant prostate cancers, with treatment-emergent small cell neuroendocrine carcinomas (t-SCNC) being the most common. In this study, we report the clinical, histopathologic, and genomic features of 126 t-SCNCs and 14 other treatment-emergent variant histologies. This retrospective multi-institutional analysis included cases from six academic cancer centers. Molecular testing was acquired from baseline adenocarcinoma biopsies (n = 23) and other variant histology biopsies (n = 74), including 21 paired samples. A total of 140 treatment-emergent variant prostate cancers were included. Prior to variant histology detection, 48% received androgen deprivation therapy (ADT) alone, 16% received ADT plus an androgen receptor pathway inhibitor (ARPI), 15% received ADT plus chemotherapy, and 20% received triplet therapy (ADT, an ARPI, and chemotherapy). In t-SCNC, prior chemotherapy [HR, 1.75; 95% confidence interval (CI), 1.16\u20132.64; adjusted P = 0.002] or ADT plus ARPI (HR, 3.04; 95% CI, 1.73\u20135.33; adjusted P = 0.009) was associated with a shorter interval from metastatic hormone-sensitive prostate cancer diagnosis to t-SCNC detection. TP53 alterations were found in 74% of baseline samples, significantly enriched compared with other cohorts of hormone-sensitive tumors. In paired biopsies, RB1 alterations were markedly increased in t-SCNC compared with baseline (76% vs. 10%, P &amp;lt; 0.001). When considering combined inactivation of key tumor suppressor genes (TSG; TP53, RB1, and PTEN), 76% had dual loss, whereas 33% harbored alterations in all three, portending worse outcomes (HR, 2.12; 95% CI, 1.03\u20134.37; univariate P = 0.041). Prior systemic treatment exposures were associated with the timing of t-SCNC detection within this selected cohort. Deleterious TP53 alterations were detected in three quarters of baseline tumors, with additional TSG losses (especially in RB1) emerging in the t-SCNC lesion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>t-SCNC is an aggressive resistance phenotype lacking validated predictive or preventive strategies. In this selected cohort, baseline TP53 alterations were common, whereas paired analyses showed increased RB1 alterations at t-SCNC detection. These findings support longitudinal molecular profiling to characterize t-SCNC evolution and identify lineage plasticity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-26-0370","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:36:44Z","timestamp":1790707004000},"page":"2505-2518","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical and Molecular Profiles of Treatment-Emergent Small Cell Neuroendocrine Prostate Cancers in the Era of Intensified Systemic Therapies"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7335-9319","authenticated-orcid":false,"given":"Nadeem","family":"Bilani","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/000e0be47","id-type":"ROR","asserted-by":"publisher"}],"name":"Northwestern University 1 Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, , Chicago, Illinois."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1566-530X","authenticated-orcid":false,"given":"Jesenia M.","family":"Perez","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/017zqws13","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Minnesota 2 Division of Hematology, Oncology, and Transplantation, Department of Medicine, Masonic Cancer Center, , Minneapolis, Minnesota."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0900-0923","authenticated-orcid":false,"given":"Ana M.","family":"Aparicio","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Texas MD Anderson Cancer Center 3 Department of Genitourinary Medical Oncology, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6869-5382","authenticated-orcid":false,"given":"Carolina","family":"Colli-Cruz","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Texas MD Anderson Cancer Center 3 Department of Genitourinary Medical Oncology, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3938-2627","authenticated-orcid":false,"given":"Cora N.","family":"Sternberg","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02r109517","id-type":"ROR","asserted-by":"publisher"}],"name":"Weill Cornell Medicine 4 Englander Institute for Precision Medicine, , Meyer Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9428-4125","authenticated-orcid":false,"given":"Daniela","family":"Guevara","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02r109517","id-type":"ROR","asserted-by":"publisher"}],"name":"Weill Cornell Medicine 4 Englander Institute for Precision Medicine, , Meyer Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8062-6431","authenticated-orcid":false,"given":"Ella","family":"Boytim","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/017zqws13","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Minnesota 2 Division of Hematology, Oncology, and Transplantation, Department of Medicine, Masonic Cancer Center, , Minneapolis, Minnesota."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5451-5726","authenticated-orcid":false,"given":"Peter S.","family":"Nelson","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/007ps6h72","id-type":"ROR","asserted-by":"publisher"}],"name":"Fred Hutchinson Cancer Center 5 Divisions of Human Biology and Clinical Research, , Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3922-5683","authenticated-orcid":false,"given":"Erolcan","family":"Sayar","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/007ps6h72","id-type":"ROR","asserted-by":"publisher"}],"name":"Fred Hutchinson Cancer Center 5 Divisions of Human Biology and Clinical Research, , Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0809-6425","authenticated-orcid":false,"given":"Michael C.","family":"Haffner","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/007ps6h72","id-type":"ROR","asserted-by":"publisher"}],"name":"Fred Hutchinson Cancer Center 5 Divisions of Human Biology and Clinical Research, , Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3740-1612","authenticated-orcid":false,"given":"Adam","family":"Sharp","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/043jzw605","id-type":"ROR","asserted-by":"publisher"}],"name":"Institute of Cancer Research 6 , Royal Marsden NHS Foundation Trust, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0203-3987","authenticated-orcid":false,"given":"Ossian","family":"Longoria","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/043jzw605","id-type":"ROR","asserted-by":"publisher"}],"name":"Institute of Cancer Research 6 , Royal Marsden NHS Foundation Trust, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2034-595X","authenticated-orcid":false,"given":"Johann","family":"de Bono","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/043jzw605","id-type":"ROR","asserted-by":"publisher"}],"name":"Institute of Cancer Research 6 , Royal Marsden NHS Foundation Trust, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4576-5034","authenticated-orcid":false,"given":"David J.","family":"VanderWeele","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/000e0be47","id-type":"ROR","asserted-by":"publisher"}],"name":"Northwestern University 1 Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, , Chicago, Illinois."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1686-7103","authenticated-orcid":false,"given":"Justin","family":"Hwang","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/017zqws13","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Minnesota 2 Division of Hematology, Oncology, and Transplantation, Department of Medicine, Masonic Cancer Center, , Minneapolis, Minnesota."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0031-9655","authenticated-orcid":false,"given":"Emmanuel S.","family":"Antonarakis","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/017zqws13","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Minnesota 2 Division of Hematology, Oncology, and Transplantation, Department of Medicine, Masonic Cancer Center, , Minneapolis, Minnesota."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0380-9465","authenticated-orcid":false,"given":"Maha","family":"Hussain","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/000e0be47","id-type":"ROR","asserted-by":"publisher"}],"name":"Northwestern University 1 Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, , Chicago, Illinois."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,10,26]]},"reference":[{"key":"2026102608433350300_bib1","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/j.1365-2559.2011.04039.x","article-title":"Histological variants of prostatic carcinoma and their significance","volume":"60","author":"Humphrey","year":"2012","journal-title":"Histopathology"},{"key":"2026102608433350300_bib2","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1200\/JCO.2017.77.6880","article-title":"Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study","volume":"36","author":"Aggarwal","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026102608433350300_bib3","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1158\/1541-7786.MCR-18-1101","article-title":"Whole-genome and transcriptional analysis of treatment-emergent small-cell neuroendocrine prostate cancer demonstrates intraclass heterogeneity","volume":"17","author":"Aggarwal","year":"2019","journal-title":"Mol Cancer Res"},{"key":"2026102608433350300_bib4","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nm.4045","article-title":"Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer","volume":"22","author":"Beltran","year":"2016","journal-title":"Nat Med"},{"key":"2026102608433350300_bib5","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.ccell.2017.09.003","article-title":"Androgen receptor pathway-independent prostate cancer is sustained through FGF signaling","volume":"32","author":"Bluemn","year":"2017","journal-title":"Cancer Cell"},{"key":"2026102608433350300_bib6","doi-asserted-by":"publisher","first-page":"3621","DOI":"10.1158\/1078-0432.CCR-12-3791","article-title":"Platinum-based chemotherapy for variant castrate-resistant prostate cancer","volume":"19","author":"Aparicio","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2026102608433350300_bib7","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1097\/PAS.0000000000000208","article-title":"Proposed morphologic classification of prostate cancer with neuroendocrine differentiation","volume":"38","author":"Epstein","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"2026102608433350300_bib8","doi-asserted-by":"publisher","first-page":"320","DOI":"10.5858\/arpa.2019-0434-RA","article-title":"Morphologic spectrum of neuroendocrine tumors of the prostate: an updated review","volume":"144","author":"Hu","year":"2020","journal-title":"Arch Pathol Lab Med"},{"key":"2026102608433350300_bib9","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/his.70033","article-title":"Molecular subtypes of metastatic prostate cancer: from pathophysiology to diagnosis","volume":"88","author":"Dsouza","year":"2026","journal-title":"Histopathology"},{"key":"2026102608433350300_bib10","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1158\/1078-0432.CCR-24-2061","article-title":"Framework for the pathology workup of metastatic castration-resistant prostate cancer biopsies","volume":"31","author":"Haffner","year":"2025","journal-title":"Clin Cancer Res"},{"key":"2026102608433350300_bib11","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1097\/PAS.0b013e318058a96b","article-title":"Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases","volume":"32","author":"Wang","year":"2008","journal-title":"Am J Surg Pathol"},{"key":"2026102608433350300_bib12","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1200\/JCO-25-00007","article-title":"Systemic therapy in patients with metastatic castration-resistant prostate cancer: ASCO guideline update","volume":"43","author":"Garje","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026102608433350300_bib13","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1016\/S1470-2045(19)30408-5","article-title":"Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1\u20132 trial","volume":"20","author":"Corn","year":"2019","journal-title":"Lancet Oncol"},{"issue":"16_suppl","key":"2026102608433350300_bib14","doi-asserted-by":"publisher","first-page":"5008","DOI":"10.1200\/jco.2025.43.16_suppl.5008","article-title":"C3NIRA: randomized phase II study of carboplatin-cabazitaxel-cetrelimab (anti-PD-1) induction followed by niraparib \u00b1 cetrelimab maintenance in men with aggressive variant prostate cancers (AVPC)","volume":"43","author":"Aparicio","year":"2025","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"2026102608433350300_bib15","doi-asserted-by":"publisher","first-page":"5012","DOI":"10.1200\/JCO.2024.42.16_suppl.5012","article-title":"Phase 1b study of tarlatamab in de novo or treatment-emergent neuroendocrine prostate cancer (NEPC)","volume":"42","author":"Aggarwal","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026102608433350300_bib16","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1038\/s41467-021-22139-7","article-title":"Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer","volume":"12","author":"Baca","year":"2021","journal-title":"Nat Commun"},{"key":"2026102608433350300_bib17","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1080\/15592294.2016.1146851","article-title":"Differentially methylated genes and androgen receptor re-expression in small cell prostate carcinomas","volume":"11","author":"Kleb","year":"2016","journal-title":"Epigenetics"},{"key":"2026102608433350300_bib18","doi-asserted-by":"publisher","first-page":"e53701","DOI":"10.1371\/journal.pone.0053701","article-title":"Sox2 is an androgen receptor-repressed gene that promotes castration-resistant prostate cancer","volume":"8","author":"Kregel","year":"2013","journal-title":"PLoS One"},{"key":"2026102608433350300_bib19","doi-asserted-by":"publisher","first-page":"5775","DOI":"10.1038\/s41467-021-26042-z","article-title":"Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer","volume":"12","author":"Cejas","year":"2021","journal-title":"Nat Commun"},{"key":"2026102608433350300_bib20","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1158\/2159-8290.CD-15-1263","article-title":"The master neural transcription factor BRN2 is an androgen receptor-suppressed driver of neuroendocrine differentiation in prostate cancer","volume":"7","author":"Bishop","year":"2017","journal-title":"Cancer Discov"},{"key":"2026102608433350300_bib21","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.ccell.2016.09.005","article-title":"N-Myc induces an EZH2-mediated transcriptional program driving neuroendocrine prostate cancer","volume":"30","author":"Dardenne","year":"2016","journal-title":"Cancer Cell"},{"key":"2026102608433350300_bib22","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1158\/2159-8290.CD-11-0130","article-title":"Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets","volume":"1","author":"Beltran","year":"2011","journal-title":"Cancer Discov"},{"key":"2026102608433350300_bib23","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1158\/1541-7786.MCR-19-1245","article-title":"Targeting RET kinase in neuroendocrine prostate cancer","volume":"18","author":"VanDeusen","year":"2020","journal-title":"Mol Cancer Res"},{"key":"2026102608433350300_bib24","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1158\/1078-0432.CCR-15-1259","article-title":"Combined tumor suppressor defects characterize clinically defined aggressive variant prostate cancers","volume":"22","author":"Aparicio","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2026102608433350300_bib25","doi-asserted-by":"publisher","first-page":"11428","DOI":"10.1073\/pnas.1902651116","article-title":"Genomic correlates of clinical outcome in advanced prostate cancer","volume":"116","author":"Abida","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026102608433350300_bib26","doi-asserted-by":"publisher","first-page":"e2200195","DOI":"10.1200\/PO.22.00195","article-title":"Genomic biomarkers and genome-wide loss-of-heterozygosity scores in metastatic prostate cancer following progression on androgen-targeting therapies","volume":"6","author":"Zurita","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"2026102608433350300_bib27","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1172\/JCI132031","article-title":"Genomics of lethal prostate cancer at diagnosis and castration resistance","volume":"130","author":"Mateo","year":"2020","journal-title":"J Clin Invest"},{"key":"2026102608433350300_bib28","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1002\/pros.24135","article-title":"Genomic profiles and clinical outcomes in primary versus secondary metastatic hormone-sensitive prostate cancer","volume":"81","author":"Nizialek","year":"2021","journal-title":"Prostate"},{"key":"2026102608433350300_bib29","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/j.eururo.2020.04.007","article-title":"CDK12 gene alterations in prostate cancer: present, but clinically actionable?","volume":"78","author":"Marciscano","year":"2020","journal-title":"Eur Urol"},{"key":"2026102608433350300_bib30","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1016\/j.cell.2018.04.034","article-title":"Inactivation of CDK12 delineates a distinct immunogenic class of advanced prostate cancer","volume":"173","author":"Wu","year":"2018","journal-title":"Cell"},{"key":"2026102608433350300_bib31","doi-asserted-by":"publisher","first-page":"7889","DOI":"10.1158\/0008-5472.CAN-06-0486","article-title":"Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer","volume":"66","author":"Zhou","year":"2006","journal-title":"Cancer Res"},{"key":"2026102608433350300_bib32","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/s43018-023-00692-y","article-title":"Multiregion sampling of de novo metastatic prostate cancer reveals complex polyclonality and augments clinical genotyping","volume":"5","author":"Warner","year":"2024","journal-title":"Nat Cancer"},{"key":"2026102608433350300_bib33","doi-asserted-by":"publisher","first-page":"e186599","DOI":"10.1172\/JCI186599","article-title":"Patterns of intra- and intertumor phenotypic heterogeneity in lethal prostate cancer","volume":"135","author":"Roudier","year":"2025","journal-title":"J Clin Invest"},{"key":"2026102608433350300_bib34","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","article-title":"Prostate cancer, version 4.2023, NCCN clinical practice guidelines in oncology","volume":"21","author":"Schaeffer","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"2026102608433350300_bib35","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1021\/acs.jmedchem.4c02768","article-title":"PSMA and SSTR2 dual-targeting theranostic agents for neuroendocrine-differentiated prostate cancer (NEPC)","volume":"68","author":"Jin","year":"2025","journal-title":"J Med Chem"},{"key":"2026102608433350300_bib36","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1530\/ERC-18-0226","article-title":"Neuroendocrine differentiation of prostate cancer leads to PSMA suppression","volume":"26","author":"Bakht","year":"2018","journal-title":"Endocr Relat Cancer"},{"key":"2026102608433350300_bib37","doi-asserted-by":"publisher","first-page":"4404","DOI":"10.3390\/cancers15174404","article-title":"PET\/CT and conventional imaging for the assessment of neuroendocrine prostate cancer: a systematic review","volume":"15","author":"Dondi","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"16_suppl","key":"2026102608433350300_bib38","doi-asserted-by":"publisher","first-page":"5059","DOI":"10.1200\/jco.2025.43.16_suppl.5059","article-title":"Phase 1b\/2 KEYNOTE-365 cohort I: pembrolizumab (pembro) plus carboplatin and etoposide chemotherapy (chemo) or chemo alone for metastatic neuroendocrine prostate cancer (NEPC)","volume":"43","author":"Von Amsberg","year":"2025","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"2026102608433350300_bib39","doi-asserted-by":"publisher","first-page":"5016","DOI":"10.1200\/jco.2026.44.16_suppl.5016","article-title":"Phase 2 multicenter trial of chemoimmunotherapy for patients with neuroendocrine or aggressive variant metastatic prostate cancer (CHAMP)","volume":"44","author":"Armstrong","year":"2026","journal-title":"J Clin Oncol"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-26-0370\/3834380\/crc-26-0370.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/10\/2505\/3842502\/crc-26-0370.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/10\/2505\/3842502\/crc-26-0370.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T12:43:44Z","timestamp":1793018624000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/6\/10\/2505\/789628\/Clinical-and-Molecular-Profiles-of-Treatment"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":39,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-26-0370","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.34789988","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34790009","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34790018","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34790006","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34790015","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34790003","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34789991","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34790012","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34789985","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34789997","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34790000","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34789994","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34790021","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8797262","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]}}}